• Profile
Close

Energy-dense vs routine enteral nutrition in the critically ill

New England Journal of Medicine Oct 25, 2018

Chapman M, et al. – Investigators conducted this multicenter, double-blind, randomized trial to test the premise that delivering a larger number of calories with the use of energy-dense enteral nutrition in patients receiving mechanical ventilation would result in higher rates of survival within 90 days vs routine care. They found that the rate of survival at 90 days related to the use of an energy-dense formulation for enteral delivery of nutrition was not higher vs routine enteral nutrition in those undergoing mechanical ventilation.

Methods

  • This trial involved adults undergoing mechanical ventilation in 46 Australian and New Zealand intensive care units (ICUs) to assess energy-dense (1.5 kcal/mL) vs routine (1.0 kcal/mL) enteral nutrition at a dose of 1 mL/kg of ideal body weight per hour, commencing at or within 12 hours of the initiation of nutrition support and continuing for up to 28 days while the patient was in the ICU.
  • All-cause mortality within 90 days was the primary outcome.

Results

  • A total of 3,957 patients were included in the modified intention-to-treat analysis (1,971 in the 1.5-kcal group and 1,986 in the 1.0-kcal group).
  • Findings revealed that the volume of enteral nutrition delivered during the trial was comparable in the two groups.
  • However, patients in the 1.5-kcal group received a mean (± SD) of 1,863 ± 478 kcal per day vs 1,262 ± 313 kcal per day in the 1.0-kcal group (mean difference, 601 kcal per day; 95% CI: 576-626).
  • An aggregate of 523 of 1948 patients (26.8%) in the 1.5-kcal group and 505 of 1966 patients (25.7%) in the 1.0-kcal group died (relative risk, 1.05; 95% CI: 0.94-1.16; P=0.41) by day 90.
  • In seven predefined subgroups, the outcomes were comparable.
  • It was noted that higher calorie delivery did not affect survival time, receipt of organ support, number of days alive and out of the ICU and hospital or free of organ support, or the incidence of infective complications or adverse events.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay